



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> :  A61K 9/00, 47/48		A1	(11) International Publication Number: WO 94/20069  (43) International Publication Date: 15 September 1994 (15.09.94)		
(21) International Application Number: PCT/US94/01875		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).			
(22) International Filing Date: 22 February 1994 (22.02.94)					
(30) Priority Data: 08/028,087 8 March 1993 (08.03.93) US					
(71) Applicant: AMGEN INC. [US/US]; Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789 (US).		<b>Published</b> <i>With international search report.</i>			
(72) Inventors: NIVEN, Ralph; 853 Vista Arriago, Camarillo, CA 93010 (US). PITI, Colin, G.; 2379 Leeward Circle, Thousand Oaks, CA 91361 (US).					
(74) Agents: ODRE, Steven, M. et al.; Amgen Inc., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789 (US).					
(54) Title: PULMONARY ADMINISTRATION OF GRANULOCYTE COLONY STIMULATING FACTOR					
(57) Abstract					
Methods and compositions for pulmonary delivery of chemically modified G-CSF, and pegylated proteins are disclosed.					

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

PULMONARY ADMINISTRATION OF  
GRANULOCYTE COLONY STIMULATING FACTOR

FIELD OF THE INVENTION

5

The present invention relates to the pulmonary administration of a therapeutic protein and, more particularly, to the systemic administration via the respiratory system of therapeutically effective amounts 10 of granulocyte colony stimulating factor (G-CSF) or chemically modified G-CSF. In another aspect, the present invention relates to the pulmonary administration of a pegylated protein.

15

BACKGROUND OF THE INVENTION

G-CSF is a hormone-like glycoprotein which regulates hematopoiesis and is required for the clonal growth and maturation of normal hematopoietic precursor 20 cells found in the bone marrow; Welte et al., *Proc. Natl. Acad. Sci.*, Vol. 82, pp. 1526-1530 (1985). More specifically, G-CSF, when present in low concentrations, is known to stimulate the production of neutrophil granulocytic colonies when used *in vitro*. G-CSF is also 25 known to enhance neutrophil migration; Gabrilove, J., *Seminars in Hematology*, Vol. 26, No. 2, pp. 1-4 (1989). Moreover, G-CSF can significantly increase the ability of neutrophils to kill tumor cells *in vitro* through antibody mediated cellular cytotoxicity; Souza et al., 30 *Science*, Vol. 232, pp. 61-65 (1986).

In humans, endogenous G-CSF is detectable in blood plasma; Jones et al., *Bailliere's Clinical Hematology*, Vol. 2, No. 1, pp.83-111. G-CSF is produced by fibroblasts, macrophages, T cells, trophoblasts, 35 endothelial cells and epithelial cells and is the expression product of a single copy gene comprised of

- 2 -

four exons and five introns located on chromosome seventeen. Transcription of this locus produces a mRNA species which is differentially processed, resulting in the expression of two forms of G-CSF, one version having  
5 a mature length of 177 amino acids, the other having a mature length of 174 amino acids. The form comprised of 174 amino acids has been found to have the greatest specific *in vivo* biological activity. G-CSF is species cross-reactive, such that when human G-CSF is  
10 administered to another mammal such as a mouse, canine or monkey, sustained neutrophil leukocytosis is elicited; Moore et al., *Proc. Natl. Acad. Sci.*, Vol. 84, pp. 7134-7138 (1987).

Human G-CSF can be obtained and purified from  
15 a number of sources. Natural human G-CSF (nhG-CSF) can be isolated from the supernatants of cultured human tumor cell lines. The development of recombinant DNA technology, see, for instance, U.S. Patent 4,810,643 (Souza), incorporated herein by reference, has enabled  
20 the production of commercial scale quantities of G-CSF in glycosylated form as a product of eukaryotic host cell expression, and of G-CSF in non-glycosylated form as a product of prokaryotic host cell expression.

Chemically modified G-CSF may also be  
25 obtained in numerous ways. Chemical modification may provide additional advantages, such as increasing the stability and clearance time of the therapeutic protein. A review article describing protein modification and fusion proteins is Francis, *Focus on Growth Factors* 3: 4-10 (May 1992) (published by Mediscript, Mountview Court, Friern Barnet Lane, London N20 0LD, UK). For example, see EP 0 401 384, entitled, "Chemically Modified Granulocyte Colony Stimulating Factor," which describes materials and methods for  
30 preparing G-CSF to which polyethylene glycol molecules are attached. (Such modified G-CSF is referred to  
35

- 3 -

herein as "pegylated G-CSF" or "PEG-G-CSF."). Such chemically modified G-CSF may be obtained by modifying nhG-CSF or G-CSF obtained as a product of prokaryotic or eukaryotic host cell expression.

5        G-CSF has been found to be useful in the treatment of cancer, as a means of stimulating neutrophil production to compensate for hematopoietic deficits resulting from chemotherapy or radiation therapy. The effective use of G-CSF as a therapeutic  
10      agent requires that patients be administered systemic doses of the protein. Currently, parenteral administration via intravenous, intramuscular or subcutaneous injection is the preferred route of administration to humans and has heretofore appeared to  
15      be the only practical way to deliver therapeutically significant amounts of G-CSF to the bloodstream, although attempts have been made at oral delivery; see, for example, Takada et al., *Chem. Pharm. Bull.*, Vol. 37, No. 3, pp. 838-839 (1989). Pulmonary delivery  
20      of chemically modified G-CSF has not been demonstrated previously, nor has pulmonary delivery of protein to which one or more polyethylene glycol molecules has been attached.

The pulmonary delivery of relatively large  
25      molecules is not unknown, although there are only a few examples which have been quantitatively substantiated. Leuprolide acetate is a nonapeptide with luteinizing hormone releasing hormone (LHRH) agonist activity having low oral availability. Studies with animals indicate  
30      that inhalation of an aerosol formulation of leuprolide acetate results in meaningful levels in the blood; Adjei et al., *Pharmaceutical Research*, Vol. 7, No. 6, pp. 565-569 (1990); Adjei et al., *International Journal of Pharmaceutics*, Vol. 63, pp. 135-144 (1990).

35      Endothelin-1 (ET-1), a 21 amino acid vasoconstrictor peptide produced by endothelial cells,

- 4 -

has been found to decrease arterial blood pressure when administered by aerosol to guinea pigs; Braquet et al., *Journal of Cardiovascular Pharmacology*, Vol. 13, suppl. 5, s. 143-146 (1989).

5       The feasibility of delivering human plasma α<sub>1</sub>-antitrypsin to the pulmonary system using aerosol administration, with some of the drug gaining access to the systemic circulation, is reported by Hubbard et al., *Annals of Internal Medicine*, Vol. III, No. 3, pp. 10   206-212 (1989).

Pulmonary administration of α<sub>1</sub>-proteinase inhibitor to dogs and sheep has been found to result in passage of some of that substance into the bloodstream; Smith et al., *J. Clin. Invest.*, Vol. 84, 15   pp. 1145-1146 (1989).

Experiments with test animals have shown that recombinant human growth hormone, when delivered by aerosol, is rapidly absorbed from the lung and produces faster growth comparable to that seen with subcutaneous 20   injection; Oswein et al., "Aerosolization of Proteins", Proceedings of Symposium on Respiratory Drug Delivery II, Keystone, Colorado, March, 1990. Recombinant versions of the cytokines gamma interferon (IFN-γ) and tumor necrosis factor alpha (TNF-α) have also been 25   observed in the bloodstream after aerosol administration to the lung; Debs et al., *The Journal of Immunology*, Vol. 140, pp. 3482-3488 (1988).

Pulmonary administration of pegylated proteins 30   has not been demonstrated previously, although, as noted above, chemical modification of proteins, including pegylation, has been demonstrated for a variety of proteins, including G-CSF.

- 5 -

SUMMARY OF THE INVENTION

The present invention is based on the discovery that G-CSF can be administered systemically to a mammal via the pulmonary route. Typically, this is accomplished by directing a stream of a therapeutically effective amount of G-CSF into the oral or nasal cavity of the inhaling mammal. Importantly, and surprisingly, substantial amounts of G-CSF are thereby deposited in the lung and absorbed from the lung into the bloodstream, resulting in elevated blood neutrophil levels. Moreover, this is accomplished without the necessity to resort to special measures such as the use of absorption enhancing agents or protein derivatives specifically designed to improve absorption. Pulmonary administration of G-CSF thus provides an effective non-invasive alternative to the systemic delivery of G-CSF by injection.

In another aspect, the present invention is based on the discovery that chemically modified G-CSF may be absorbed from the lung into the bloodstream. In addition to the advantages of pulmonary delivery as described above, this provides additional advantages. Chemical modification may lengthen the circulation time of the protein in the body, alter immunoreactivity, reduce toxicity, alter bioactivity, and alter certain physical properties of the therapeutic peptide.

In yet another aspect, the present invention is based on the broad discovery that a protein to which a polyethylene glycol molecule has been attached may be absorbed by the lung into the bloodstream. Polyethylene glycol, or "PEG" is a hydrophilic polymer. For example, solid PEGs are insoluble in liquid paraffin, fats and fixed oils. *Handbook of Pharmaceutical Excipients*, (American Pharmaceutical Association and The Pharmaceutical Society of Great Britain), pages 209-213

- 6 -

at 210. Further, the structure of the lung is such that while gaseous exchange is facilitated, uptake of solids or liquids is not. The membrane junctions between the epithelia cells are considered tight, and as such, would 5 not be expected to allow absorption or transfer of large hydrophilic molecules. As such, PEG is not expected to cross hydrophobic membranes to any significant degree.

The pulmonary administration of G-CSF or chemically modified G-CSF can be practiced using any 10 purified isolated polypeptide having part or all of the primary structural conformation (i.e., continuous sequence of amino acid residues) and one or more of the biological properties of naturally occurring G-CSF. A number of publications describe methods of producing 15 G-CSFs, including the above mentioned Souza patent and the Welte et al. and Nicola et al. articles.

In general, G-CSF useful in the practice of this invention may be a native form isolated pure from mammalian organisms or, alternatively, a product of 20 chemical synthetic procedures or of procaryotic or eucaryotic host expression of exogenous DNA sequences obtained by genomic or cDNA cloning or by gene synthesis. Suitable procaryotic hosts include various bacterial (e.g., *E. coli*) cells. Suitable eucaryotic 25 hosts include yeast (e.g., *S. cerevisiae*) and mammalian (e.g., Chinese hamster ovary, monkey) cells. Depending upon the host employed, the G-CSF expression product may be glycosylated with mammalian or other eucaryotic carbohydrates, or it may be non-glycosylated. The G-CSF 30 expression product may also include an initial methionine amino acid residue (at position -1). The present invention contemplates the use of any and all such forms of G-CSF, although recombinant G-CSF, especially *E. coli* derived, is preferred for reasons of 35 greatest commercial practicality.

- 7 -

The G-CSF to be chemically modified for use in the present invention may also be either nhG-CSF or the product of a recombinant nucleic acid process, such as prokaryotic or eukaryotic host cell expression. In general, chemical modification contemplated is the attachment of a chemical moiety to the G-CSF molecule itself, where said chemical moiety permits pulmonary administration of the chemically modified G-CSF. The attachment may be by bonding, directly to the protein or to a moiety which acts as a bridge to the active agent. Covalent bonding is preferred as the most stable for attachment. The chemical modification may contribute to the controlled, sustained or extended effect of the G-CSF. This may have the effect, for example, of controlling the amount of time the chemically modified G-CSF takes to reach the circulation. An example of a chemical modifier is polyethylene glycols, including derivatives thereof.

Contemplated for use in the practice of this invention are any chemically modified G-CSF preparations which permit efficacy upon pulmonary administration. Efficacy may be determined by known methods, as a practitioner in the art will recognize. PEGylated G-CSF, especially pegylated *E. coli* derived G-CSF, and more particularly, tri-tetra pegylated *E. coli* derived G-CSF (as described below) is preferred.

When attaching the chemical moiety to the G-CSF or other peptide, one should consider the location of the attachment. For example, attachment in a location affecting the receptor binding site, functional domains or antigenic domains may also affect the biological activity.

Contemplated for use in the practice of pulmonary administration of a pegylated protein are a variety of compositions for which pulmonary administration would be desired in pegylated form.

- 8 -

Exemplary proteins contemplated are cytokines, including various hematopoietic factors such as G-CSF, SCF, EPO, GM-CSF, CSF-1, IL-2 and IL-6. Other therapeutic proteins such as growth factors or hormones are also useful, such as human or other animal growth hormones (for example, bovine, porcine, or chicken growth hormone), and insulin. Plasminogen activators, such as tPA, urokinase and streptokinase are also contemplated. Also contemplated are peptide portions of proteins having all or part of the primary structural conformation of the parent protein and at least one of the biological properties of the parent protein. Analogs, such as substitution or deletion analogs, or those containing altered amino acids, such as peptidomimetics are also contemplated.

Also contemplated is use of polyethylene glycol molecules with a range of molecular weights. Preferred are those polyethylene glycol molecules which act to increase the half life of the peptide, typically those PEG molecules with a molecular weight of between about 500 and about 20,000. The term "about" is used to reflect the approximate average molecular weight of a polyethylene glycol preparation, recognizing that some molecules in the preparation will weigh more, some less. Preferred are "solid" PEGs which are insoluble in fats and oils. "Solid" PEGs are generally of MW 1000 or above, although PEG 600 can be solid at ambient temperatures. *Handbook of Pharmaceutical Excipients, supra*, page 209, which is incorporated by reference. The PEG used in the working examples described below had a molecular weight of about 6000, and acted to increase the half life of the G-CSF used.

The polyethylene glycol molecules should be attached to the peptide with consideration of effects on functional or antigenic domains as noted above. The method for attachment of the polyethylene glycol

- 9 -

molecules may vary, and there are a number of methods available to those skilled in the art. E.g., EP 0 401 384 (coupling PEG to G-CSF), see also, Malik et al, *Exp. Hematol.* 20: 1028-1035 (1992) (reporting pegylation 5 of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may 10 be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues, glutamic acid residues and the C-terminal amino acid residue. 15 Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules.

The number of polyethylene glycol molecules so attached may vary, and one skilled in the art will be able to ascertain the effect on function. As 20 noted in more detail below, the pegylated G-CSF preferred herein is tri-tetra pegylated with PEG 6000, i.e., a G-CSF molecule having three or four PEG 6000 molecules attached.

Contemplated for use in the practice of this 25 invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.

Some specific examples of commercially 30 available devices suitable for the practice of this invention are the Ultravent nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Missouri; the Acorn II nebulizer, manufactured by Marquest Medical Products, 35 Englewood, Colorado; the Ventolin metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park,

- 10 -

North Carolina; and the Spinhaler powder inhaler, manufactured by Fisons Corp., Bedford, Massachusetts.

All such devices require the use of formulations suitable for the dispensing of G-CSF.

- 5      Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usual diluents, adjuvants and/or carriers useful in G-CSF therapy. Also, the use of liposomes, microcapsules  
10     or microspheres, inclusion complexes, or other types of carriers is contemplated. Chemically modified G-CSF may also be prepared in different formulations depending on the type of chemical modification or the type of device employed. G-CSF formulations which can be utilized in  
15     the most common types of pulmonary dispensing devices to practice this invention are now described, and the same factors should be taken into consideration when formulating chemically modified G-CSF or a pegylated protein for pulmonary administration.

20

#### Nebulizer Formulations

Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically  
25     comprise G-CSF (or chemically modified G-CSF or pegylated protein) dissolved in water at a concentration of about 0.1 to 25 mg of G-CSF (or chemically modified G-CSF or pegylated protein) per mL of solution. The formulation may also include a buffer and a simple sugar  
30     (e.g., for protein stabilization and regulation of osmotic pressure). Examples of buffers which may be used are sodium acetate, citrate and glycine. Preferably, for G-CSF formulations, the buffer will have a composition and molarity suitable to adjust the solution to a pH in  
35     the range of 3 to 4. Generally, buffer molarities of from 2 mM to 50 mM are suitable for this purpose.

- 11 -

Examples of sugars which can be utilized are mannitol and sorbitol, usually in amounts ranging from 1% to 10% by weight of the formulation.

The nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol. Various conventional surfactants can be employed, such as polyoxyethylene fatty acid esters and alcohols, and polyoxyethylene sorbitan fatty acid esters. Amounts will generally range between 0.001 and 4% by weight of the formulation. An especially preferred surfactant for purposes of this invention is polyoxyethylene sorbitan monooleate.

15 Metered Dose Inhaler Formulations

Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing G-CSF (or chemically modified G-CSF or a pegylated protein) suspended in a propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.

Powder Inhaler Formulations

Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing G-CSF (or chemically modified G-CSF

- 12 -

or a pegylated protein) and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the

- 5 formulation. The G-CSF (or chemically modified G-CSF or pegylated protein) should most advantageously be prepared in particulate form with an average particle size of less than 10 mm (or microns), most preferably 0.5 to 5 mm, for most effective delivery to the  
10 distal lung.

The invention contemplates the administration of therapeutic amounts of the protein, i.e., G-CSF or chemically modified G-CSF, sufficient to achieve elevation of the neutrophil level in the systemic blood.

- 15 What constitutes a therapeutically effective amount of G-CSF or chemically modified G-CSF in a particular case will depend on a variety of factors which the knowledgeable practitioner will take into account, including the normal blood neutrophil level for that  
20 subject, the severity of the condition or illness being treated, the degree of neutropenia, the physical condition of the subject, and so forth. In general, a dosage regimen will be followed such that the normal blood neutrophil level for the individual undergoing  
25 treatment is restored, at least in cases of abnormally low or depressed blood neutrophil counts. For humans, the normal blood neutrophil level is about 5000 to 6000 neutrophils per microliter of blood. Neutrophil counts below 1000 in humans are generally regarded as  
30 indicative of severe neutropenia and as placing the subject at great risk to infection. Clinical studies with cancer patients suffering from chemotherapy-induced neutropenia have shown that subcutaneous injected doses of 3-5 mg G-CSF/kg every twenty-four hours are effective  
35 in elevating acutely deficient blood neutrophil levels above 1000. Based on preliminary results with animals,

- 13 -

described below, it is anticipated that for most mammals, including humans, the administered dose of G-CSF for pulmonary delivery (referred to here as the inhalation dose) will be about 3 to 10 times the corresponding subcutaneous dose necessary to achieve a particular blood neutrophil level.

The therapeutic dosage for chemically modified G-CSF may be ascertained taking into account the variety of factors listed above. Some chemical modification, such as pegylation, may lengthen the half-life of G-CSF in the body, and this should also be considered when ascertaining therapeutic dosage. Chemical modification may also alter immunoreactivity, reduce toxicity, alter bioactivity, and alter certain physical properties of the therapeutic protein, additional variables to consider when ascertaining therapeutic dosage of chemically modified G-CSF. PEGylated G-CSF, the chemically modified G-CSF used herein as an example, is known to have a serum half-life greater than that of non-PEGylated G-CSF.

For other pegylated proteins, one skilled in the art should consider that pegylation may modify the pharmacological properties of proteins, usually extending the plasma half-life and concomitantly increasing *in vivo* bioactivity, and may reduce antigenicity and immunogenicity. There may also be an increase in solubility and resistance to proteolysis. For other general considerations when determining dosages, see Remington's Pharmaceutical Sciences, 18th Ed. 1990 (Mack Publishing Co., Easton PA) Chapter 35.

As those skilled in the art will recognize, the operating conditions for delivery of a suitable inhalation dose will vary according to the type of mechanical device employed. For some aerosol delivery systems, such as nebulizers, the frequency of administration and operating period will be dictated

- 14 -

chiefly by the amount of G-CSF or other active composition per unit volume in the aerosol. In general, the higher the concentration of protein in the nebulizer solution the shorter the operating period. Some devices 5 such as metered dose inhalers may produce higher aerosol concentrations than others and thus will be operated for shorter periods to give the desired result.

Other devices such as powder inhalers are designed to be used until a given charge of active 10 material is exhausted from the device. The charge loaded into the device will be formulated accordingly to contain the proper inhalation dose amount of G-CSF or other active ingredient for delivery in a single administration. See generally, Remington's 15 *Pharmaceutical Sciences*, (18th Ed. 1990, Mack Publishing Co., Easton PA) Chapter 92 for information relating to aerosol administration.

Regardless of what device is used for aerosolization, the active ingredients will be in the 20 form of a dispersion of particles. The dispersion of particles may be in the form of liquid droplets or in the form of powder (dry or suspended). The dispersant itself, including the G-CSF, the chemically modified G-CSF, or a pegylated protein, is the population of 25 particles which is emitted from the delivery device for deposition within the lung. As set forth above, an average particle size (mass median diameter) of less than 10 mm (or microns), most preferably 0.5 to 5 mm, is used for most effective delivery to the distal lung. 30 For example, the dispersion of particles may consist essentially of pegylated protein, such as the pegylated G-CSF described herein, in a pharmaceutically acceptable carrier.

While G-CSF has been found useful in treating 35 neutrophil-deficient conditions such as chemotherapy related neutropenia, G-CSF is expected to also be

- 15 -

effective in combating infections and in treating other conditions or illnesses where blood neutrophil levels elevated above the norm can result in medical benefit. As further studies are conducted, information will  
5 emerge regarding appropriate dosage levels for the administration of G-CSF in these latter cases. Also, as further studies are accomplished using pegylated G-CSF, it is expected that appropriate formulations and dosages will be ascertained for the same uses. It is expected  
10 that the present invention will be applicable as a non-invasive alternative in most instances where G-CSF (or chemically modified G-CSF or a pegylated proteins) is administered therapeutically by injection.

15

BRIEF DESCRIPTION OF THE DRAWINGS

20

FIGURE 1 is a graphical depiction of the effect of subcutaneously administered rhG-CSF on blood neutrophil levels in hamsters.

25

FIGURE 2 is a bar graph of the blood neutrophil levels in hamsters following exposure to aerosols generated from either an Acorn II nebulizer or an Ultravent nebulizer, using different concentrations of rhG-CSF in aqueous solution.

30

FIGURE 3 depicts a comparison of blood neutrophil levels resulting from subcutaneous and aerosol administration of rhG-CSF.

35

FIGURE 4 is a graph of the white blood cell count at time intervals 0-6 hours after pulmonary administration of 50 $\mu$ g of pegylated G-CSF.

- 16 -

FIGURE 5 is a bar graph of the effects of pegylated G-CSF on circulating cell differentials up to six hours after intratracheal administration.

5 FIGURE 6 is a graph of the circulating neutrophil and macrophage numbers from zero to six hours after intratracheal instillation of 50 $\mu$ g pegylated G-CSF.

10 FIGURE 7 is a graph of the circulating white blood cell counts after intratracheal instillation of 50 $\mu$ g pegylated G-CSF over 5 days.

15 FIGURE 8 is a graph of the weight change of animals after a single intratracheal dose of 50 $\mu$ g non-pegylated G-CSF.

20 FIGURE 9 is a graph of the differential cell types in circulation after intratracheal instillation of 500 $\mu$ g/kg pegylated G-CSF.

FIGURE 10 is a graph of cell types in bronchoaveolar lavage ("BAL") after intratracheal instillation of 500 $\mu$ g/kg pegylated G-CSF.

25 FIGURE 11 is a bar graph illustrating the effect on white blood cell count number using an inhaled anesthetic vs. using no inhaled anesthetic 24 hours after intratracheal instillation of 50 $\mu$ g non-pegylated G-CSF.

FIGURE 12 is a bar graph of neutrophils in BAL after intratracheal instillation of 50 $\mu$ g non-pegylated G-CSF.

- 17 -

FIGURE 13 is a graph of the relative concentrations of pegylated G-CSF and non-pegylated G-CSF in BAL and serum after intratracheal instillation as determined by immunoassay.

5

FIGURE 14 is a graph of the logarithmic transformation of the rate that either pegylated or non-pegylated G-CSF is absorbed from the lungs as presented in micrograms present in BAL vs. time, with absorption rate constants ((ka)/hr)).

10 FIGURE 15 is a graph of the dose response curve (logarithmic) to instilled and subcutaneous injection tri-tetra pegylated G-CSF.

15

FIGURE 16 is a graph of the increase in circulating white blood cell counts after a single intra-cardiac injection of 500 $\mu$ g/kg G-CSF tri-tetra pegylated G-CSF or HCl vehicle.

20

FIGURE 17 is a graph of the comparison of the white blood cell counts after the intratracheal instillation or intra-cardiac injection of 500 $\mu$ g/kg pegylated G-CSF.

25

FIGURE 18 is a graph of the comparison of white blood cell counts after the intratracheal instillation or intra-cardiac injection of 500 $\mu$ g/kg non-pegylated G-CSF.

30

#### DETAILED DESCRIPTION

As mentioned, parenteral administration of G-CSF is known to cause an increase in the number of neutrophils in the peripheral blood. Studies were 35 performed to demonstrate that inhalation of an aerosol

- 18 -

of recombinant human G-CSF (rhG-CSF) also causes an increase in the number of blood neutrophils. The rhG-CSF employed was an *E. coli* derived recombinant expression product having the amino acid sequence shown in FIGURE 7  
5 of the aforementioned Souza patent comprising the entire hG-CSF polypeptide with an amino terminal methionine group. It can be made by use of the same procedure described therein.

The pulmonary administration of chemically  
10 modified G-CSF is also described herein, using rhG-CSF (as described above) to which polyethylene glycol molecules have been attached. The use of pegylated G-CSF for pulmonary administration demonstrates that chemically modified G-CSF, and, in another respect, a  
15 pegylated protein, can be absorbed through the lung.

#### Aerosol Administration of rhG-CSF

20

#### EXAMPLE 1

##### Subcutaneous Administration to Hamsters

Initial experiments were performed to measure the change in the number of neutrophils in the blood of  
25 4-6 week old male Golden Syrian hamsters (Charles River Laboratories, Wilmington, Massachusetts), following subcutaneous administration of various doses of rhG-CSF. The rhG-CSF was prepared as a 4 mg/ml solution in sterile distilled water, diluted in sterile 0.9% saline  
30 solution, and different volumes were immediately injected subcutaneously in the lower back of hamsters in test groups of 3 to 5 animals. Twenty-four hours later, blood was collected from each hamster by cardiac puncture under halothane anesthesia. The number of  
35 neutrophils in the blood was determined by performing differential and complete blood cell counts. Results of

- 19 -

these experiments, shown in FIGURE 1, indicate a dose-dependent increase in the number of neutrophils twenty-four hours after injection of rhG-CSF is observed for doses up to approximately 100 micrograms per 5 kilogram of body weight (mg/kg). The dose response curve appeared to level off at greater doses.

#### EXAMPLE 2

10

#### Aerosol Characterization and Administration

15

Inhalation exposures to aerosols containing rhG-CSF were conducted using a small animal exposure chamber manufactured by In-Tox Products (Albuquerque, NM). Only the central 12 ports in the animal chamber were used; the peripheral ports in the aerosol distribution manifold in the animal chamber were sealed. With this modification to the chamber, the air supplied by a nebulizer was adequate to maintain 10 hamsters during an exposure. Filter samples were taken from one of the animal ports and from the air exhaust line to measure the aerosol concentration in the exposure chamber. The aerosol was sampled from the remaining available animal port, and particle size 20 distribution measurements with a QCM (quartz crystal monitor) cascade impactor (California Instruments, Inc., Sierra Madre, CA) were taken periodically throughout an exposure. This cascade impactor draws only 240 mL/min, which allows the particle size 25 distribution of the aerosol to be measured without disturbing the airflow pattern in the exposure chamber.

30

35

35

Prior to conducting the animal exposure studies, the aerosol concentration and particle size distribution of aerosols generated from a 20 mg/mL albumin solution, using either the Ultravent nebulizer or the Acorn II nebulizer (both jet type), were

- 20 -

measured in the exposure chamber. Table 1 shows the particle size distribution and the average albumin concentration in the aerosol measured at two locations (nose and outlet) in the chamber. The Ultravent  
 5 produced an aerosol having much smaller particles than the Acorn II, but the Acorn II produced a more concentrated aerosol. It was found that the two nebulizers delivered a roughly equivalent amount of protein to an animal when the devices were operated  
 10 until the initial charge of 5 mL was exhausted and aerosol generation became erratic (10 or 15 minutes for the Acorn II depending on the operating air flow rate, and 20 minutes for the Ultravent).

15

TABLE 1  
 AEROSOL CONCENTRATION AND INHALATION DOSE  
 ESTIMATES FOR TWO JET NEBULIZERS USING A  
 20 mg/ml ALBUMIN SOLUTION

Nebulizer	Conc. µg/L ± SEM	Aerosol	MMAD	Delivered	
		(µm)*	GSD	Period (minute)	Dose µg/L± SEM
Ultravent	outlet 126 ± 13	0.93	20	76 ± 8	
10 L/min	nose 141 ± 17	3.6	20	85 ± 10	
Acorn II	outlet 239 ± 48	2.8	15	107 ± 29	
8 L/min	nose 141 ± 17	2.9	15	133 ± 3	
10 L/min	outlet 362	--	10	109	

20

\* MMAD = Mass median aerodynamic diameter; GSD = Geometric standard deviation; SEM = standard error of the mean of three determinations

25

An estimate of the amount of G-CSF delivered via aerosol to a hamster during an inhalation exposure

- 21 -

from a nebulizer was determined from the following expression:

$$D = hVCdt$$

where D is the inhalation dose, h is the fractional deposition, V is the ventilation rate, C is the aerosol concentration, and dt is the period of administration. By using the measured aerosol concentration (C) and operating period ( $\Delta t$ ) of the nebulizer, along with the resting ventilation rate (V) for a mature hamster of 10 30 mL/min and a fractional deposition (h) of 0.5, it was determined that G-CSF concentrations of between 5 mg/mL and 10 mg/mL of nebulizer solution would result in an inhalation dose of 100 mg/kg (e.g., 10 mg for a 100 g hamster). This was the dose estimated to produce a 15 maximal neutrophil response via pulmonary delivery.

### EXAMPLE 3

#### Aerosol Administration of G-CSF to Hamsters

20

The solutions used to conduct aerosol exposures were prepared by reconstituting lyophilized rhG-CSF in sterile distilled water containing 1 mg/mL of the nonionic surfactant polyoxyethylenesorbitan 25 monooleate. The solutions used in the nebulizer to generate the exposure aerosols were prepared with G-CSF in concentrations ranging from 1 to 15 mg/mL.

Groups of ten hamsters (mature, male Golden Syrian) were exposed to aerosols containing rhG-CSF. The 30 hamsters were placed in restraining tubes and allowed to acclimate for approximately 5 minutes. The tubes were then inserted into the exposure chamber and the aerosol exposure was initiated. Following exposure, the hamsters were returned to their cages and given free access to 35 food and water. Blood samples were taken 24 hours after exposure, and the blood neutrophil concentration was

- 22 -

determined by the same procedure used to evaluate the blood samples following subcutaneous injection.

The aerosol concentration and particle size distribution were measured during each exposure. The

5 G-CSF dose was varied from one exposure to another by using different concentrations of G-CSF in the nebulizer solution.

Hamsters exposed to aerosols containing G-CSF were found to have elevated neutrophil concentrations  
10 when compared to untreated animals and animals exposed to an aerosol containing only water and surfactant (polyoxyethylene sorbitum monooleate). FIGURE 2 shows the increase in neutrophil counts observed in animals exposed to aerosols generated from rhG-CSF nebulizer  
15 solutions ranging in concentration as described. As can be seen, the circulating neutrophil levels obtained from G-CSF aerosol exposure, even with as low a concentration as 1 mg/mL of G-CSF (using the Ultravent nebulizer), were significantly higher ( $p<0.05$ ) than the  
20 group exposed to an aerosol without G-CSF. The statistical significance of the increase in neutrophil levels over the control was  $p<0.001$  for all the other groups. The increase in blood neutrophil levels correlated with increasing G-CSF concentration in the  
25 nebulizer solution up to a concentration of 5 mg/mL. A maximum response of 15,000 neutrophils per mL of blood was observed with the more concentrated G-CSF nebulizer solutions, similar to the maximum obtained with subcutaneous injection of doses greater than 50 mg/kg.  
30 There was virtually no difference in neutrophil response obtained with the two nebulizers using lower G-CSF solution concentrations, e.g., below 5 mg/mL. For G-CSF solution concentrations greater than 5 mg/mL, the Acorn II nebulizer produced a greater increase in  
35 neutrophil response than the Ultravent.

- 23 -

An inhalation exposure to an aerosol generated from a 5 mg/mL G-CSF solution that did not contain surfactant produced a neutrophil response ( $9,910 \pm 960$  neutrophils/ $\mu\text{L}$ ) in hamsters not significantly different  
5 from that obtained with either a 50  $\mu\text{g}/\text{kg}$  subcutaneous injection containing surfactant ( $10,935 \pm 1,390$  neutrophils/ $\mu\text{L}$ ) or a 50  $\mu\text{g}/\text{kg}$  subcutaneous injection prepared from the solution lacking surfactant ( $10,270 \pm 430$  neutrophils/ $\mu\text{L}$ ). These values are reported  
10 as the mean and standard error of ten animals for the aerosol tests and five animals for the injections. From this experiment, it was concluded that the surfactant was not a necessary component of the aqueous aerosol formulation for G-CSF.

15

#### EXAMPLE 4

##### Fractional Deposition of G-CSF Aerosol in Hamster Lungs

20

The dose delivered to the animal during an exposure was estimated in order to ascertain whether therapeutic amounts of G-CSF can be effectively and economically delivered via the lung. The delivered or  
25 deposited dose is the product of the amount of drug the animal inhales and the efficiency (fractional deposition) with which the aerosol particles deposit in the lung. The latter was determined by measurement of the amount of G-CSF recovered from the hamster lungs  
30 following aerosol exposure.

G-CSF deposited in the lungs was measured in two groups of four animals exposed to aerosols generated with the Acorn II nebulizer. Immediately following aerosol exposure, the whole lungs of four hamsters were  
35 removed, placed into glass tissue grinders containing 3 mL of cold physiological buffered saline, and

- 24 -

homogenized. The homogenate was centrifuged twice, and the final supernatent was transferred to a clean tube and assayed for G-CSF using radioimmunoassay (Amgen Inc., Thousand Oaks, CA). In control experiments 5 using this procedure, it was determined that 75% of the G-CSF could be recovered from samples of lung homogenate spiked with a known amount of G-CSF. All measurements of G-CSF in the lungs following aerosol exposure were corrected for this fractional recovery of G-CSF from 10 lung tissue.

An average of  $3.1 \pm 0.3 \mu\text{g}$  of G-CSF was deposited in the lung in the group of animals exposed for 11 minutes to an aerosol generated from a 5 mg/mL solution of the protein. An average of  $20.0 \pm 4.0 \mu\text{g}$  of 15 G-CSF was deposited in the animal group exposed for 11 minutes to an aerosol generated from a 20 mg/mL solution. Based on the concentration of G-CSF in the aerosol measured during the exposure and the resting ventilation rate (30 mL/min), the animals in the 5-mg/mL 20 group inhaled 22  $\mu\text{g}$  of G-CSF ( $68 \mu\text{g}/\text{L} \times 0.030 \text{ L}/\text{min} \times 11 \text{ min}$ ), and the 20-mg/mL group inhaled 69  $\mu\text{g}$  of G-CSF ( $208 \mu\text{g}/\text{L} \times 0.030 \text{ L}/\text{min} \times 11 \text{ min}$ ) over an exposure period. Using the amounts of G-CSF inhaled and the amounts recovered from the lung, the deposition 25 efficiency (fractional deposition  $\times 100$ ) in the lung was estimated to be 14% for the 5-mg/mL group and 29% for the 20-mg/mL group.

The fractional deposition determined from the G-CSF measured in the lungs following aerosol exposure 30 was then used to estimate the G-CSF dose administered by aerosol, in order to relate the increase in the neutrophil concentration to the aerosol dose.

Table 2 contains the inhaled and deposited doses estimated for the aerosol exposures using various 35 concentrations of G-CSF in the nebulizer solution. The G-CSF aerosol concentration was measured gravimetrically

- 25 -

from a filter sample collected during the exposure and the weight was corrected for the proportion of surfactant (1 mg/mL) to G-CSF in solution. The inhaled dose was calculated from the aerosol concentration, the 5 resting ventilation rate (30 mL/min), and the exposure period (11 minutes for the Acorn II and 20 minutes for the Ultravent). The deposited dose was calculated from the inhaled dose and the measured fractional deposition (0.29).

10

TABLE 2  
THE ESTIMATES OF G-CSF DELIVERED  
TO THE LUNG DURING AEROSOL EXPOSURES

Solution	[C]*	Inhaled Dose (μg)	Deposited dose (μg)	Mean Body Weight (g)	Estimated Dose/Body Wt. (μg/kg)
Conc (mg/ml)					
		Acorn II	Nebulizer		
1	8	2.6	0.75	66.7	11
2	10	3.3	0.96	76.3	13
5	73	24	7.0	92.2	76
10	109	36	10	83.3	125
15	188	62	18	86.1	209
Ultravent Nebulizer					
1	2.5	1.5	0.44	63.3	6.9
2	2.7	1.6	0.46	77.1	6.1
5	33	20	5.7	91.2	63
10	41	25	7.1	84.8	84
15	38	23	6.6	81.5	81

15

FIGURE 3 shows the neutrophil response following subcutaneous injection and the aerosol administration of G-CSF for the dose levels calculated

- 26 -

above. Comparing the neutrophil response obtained with an aerosol to that obtained by subcutaneous injection shows that, for the therapeutically important dose range of 1 to 100 µg/kg, the deposited dose is approximately  
5 equivalent to an injection.

While this invention has been specifically illustrated with regard to the use of aerosolized solutions and nebulizers, it is to be understood that  
10 any conventional means suitable for pulmonary delivery of a biological material may be employed to administer G-CSF in accordance with this invention. Indeed, there may be instances where a metered dose inhaler, or powder inhaler, or other device is preferable or best suits  
15 particular requirements. The foregoing description provides guidance as to the use of some of those devices. The application of still others is within the abilities of the skilled practitioner. Thus, this invention should not be viewed as being limited to  
20 practice by application of only the particular embodiments described.

Examples Using Chemically Modified G-CSF

25 Examples 5-8 below demonstrate that chemically modified G-CSF may also be administered systemically, with biological activity *in vivo* equaling or exceeding the efficacy of non-pegylated G-CSF. In mammals, pegylated G-CSF not only caused an increase in  
30 total white blood cell count, but also the production of a greater number of white blood cells than similar administration of non-pegylated G-CSF. Furthermore, the numbers of white blood cells were sustained for a longer period with pegylated G-CSF, than for  
35 non-pegylated G-CSF.

- 27 -

The examples using pegylated G-CSF also demonstrate that pulmonary administration is unexpectedly efficacious for pegylated proteins.

In Example 5 pulmonary administration of 5 pegylated G-CSF via intratracheal instillation was compared to pulmonary administration of non-pegylated recombinant G-CSF. Two observations are notable:  
(a) the pegylated G-CSF was absorbed from the lungs to the blood stream, and remained in the blood stream  
10 longer than non-pegylated G-CSF; and (b) overtime, the increase in total white blood cells was higher and was maintained longer with the pegylated G-CSF than with non-pegylated G-CSF.

In Example 6, immunoassays were performed to 15 determine how long G-CSF is detected in serum when administered to the lungs in pegylated vs. non-pegylated form. These data indicate that pegylated G-CSF transfers out of the lung more slowly than non-pegylated G-CSF, and reaches a peak serum concentration approximately 20 4 hours after non-pegylated G-CSF.

In Example 7, a dose ranging study compares pulmonary administration of pegylated G-CSF to sub-cutaneous ("sc") injection of pegylated G-CSF. The results (in terms of biological activity) were similar 25 whether the pegylated G-CSF was instilled (pulmonary administration) or injection directly into the blood stream. This demonstrates further that pegylation does not prevent the G-CSF from absorbing through the lungs and having biological effect.

30 In Example 8, intra-cardiac pulmonary administration was compared to intratracheal pulmonary administration in terms of the number of total circulating white blood cells, with the following observations:

35 (a) for intra-cardiac administration of both G-CSF and pegylated G-CSF, the results are similar in

- 28 -

terms of white blood cell count and rate of white blood cell count increase; and,

(b) for pegylated G-CSF alone, comparing intra-cardiac administration vs. intratracheal

5 administration, the results are similar in terms of white blood cell count and rate of increase.

Below, the materials and methods used in examples 5-8 are first set forth. The results follow.

10 Materials and Methods

A. Preparation of Recombinant Human met-G-CSF

Recombinant human met-G-CSF was prepared as described above according to methods in the Souza 15 patent. The rhG-CSF employed was an *E. coli* derived recombinant expression product having the amino acid sequence shown in FIGURE 7 of the Souza patent (U.S. Patent No. 4,810,643 referenced above), comprising the entire hG-CSF polypeptide with an amino terminal 20 methionine group.

B. Preparation of Chemically Modified G-CSF

Recombinant human met-G-CSF with three or four polyethylene glycol molecules attached, referred to 25 herein as tri-tetra pegylated G-CSF, was used in the examples using pegylated G-CSF. Attachment was accomplished via the reactive amino groups. The mean molecular weight of the pegylated G-CSF was between about 36,500 Daltons and about 42,500 Daltons, with the 30 molecular weight of the polyethylene glycol chains being about 6000 Daltons each. A small portion of the pegylated G-CSF may have been penta-pegylated, but this portion was negligible.

The following method was used to prepare the 35 tri-tetra peglyated G-CSF used in the studies described herein:

- 29 -

One gram of recombinant human met-G-CSF, (prepared by the above method) was treated with a 15 fold molar excess of SCM-MPEG (N-hydroxy succinimidyl esters of carboxymethyl methoxy polyethylene glycol) to 5 produce predominately tri-tetra-pegylated G-CSF. The bulk formulated G-CSF was buffer exchanged with pH 4.0 Water-for-injection ("WFI"), (Baxter, Deerfield, IL) and concentrated to 12.5 mg/ml. It was then diluted 1.25 fold with 500 mM Bicine, pH8, to give G-CSF (10 mg/ml) 10 in 100 µM Bicine. The G-CSF solution was added to solid SCM-MPEG powder. After reacting for 1 hour, the mixture was diluted 5x with WFI and the pH was adjusted to 4.0 with 1N HCl.

The reaction mixture was applied to a 350 ml 15 column of Toyopearl SP550c (TosoHaas, Philadelphia, PA) which had been equilibrated with 20 mM NaOAc, pH 4.0. The reaction by-products, n-hydroxysuccinimide (NHS) and unreacted PEG, did not bind to the column. The column was washed with 3 column volumes of equilibration 20 buffer, after which PEG-G-CSF was eluted with 4 column volumes of 350 mM NaCl in 20 MM NaOAc, pH 4.0. Any unreacted G-CSF was eluted with 1M NaCl.

All of the protein containing fractions eluted with 350 mM NaCl were pooled. PEG-G-CSF was 25 concentrated, buffer exchanged into standard G-CSF buffer (1mM HCL in water) and adjusted to 1.0 mg/ml. The bulk was sterile filtered and stored in vials, 2 ml/vial, at a concentration of 1.0 mg/ml.

30       C.     Procedure For Pulmonary Administration of Pegylated G-CSF: Instillation

In the following examples using pegylated G-CSF, pulmonary administration was accomplished by injection of appropriate dosages into the trachea of 35 hamsters, a process referred to herein as instillation. The instillation procedure was used in order to

- 30 -

facilitate dosage quantification. Aerosol administration, or other forms of pulmonary administration are also applicable for chemically modified G-CSF or pegylated proteins. All animals were  
5 treated according to applicable laws and regulations for the handling of research animals.

Male golden Syrian hamsters, approximately 100 g, were anesthetized and weighed. Anesthetized animals were placed face up on a slanted board (about a  
10 60 degree angle), and supported to expose the throat. A fiber optic lamp was positioned externally directly adjacent to the throat such that the light emerging from the trachea could be observed through the mouth and the opening of the larynx thus distinguished from  
15 the esophagus.

A 1 ml dosing syringe containing 100 µl of G-CSF or pegylated G-CSF was attached to a 4 inch 20G pipetting needle. This, in turn, was sheathed by a 16 G blunt nosed needle connected to a 5 ml syringe and  
20 withdrawn to 2 ml. The purpose of the sheath was to help prevent backflushing of the dose during instillation.

The dosing needle so sheathed was passed through the mouth and approximately 1.5 cm into the  
25 trachea. Positioning within the trachea was determined by "feeling" the tracheal cartilage with the edge of the dosing needle. Once in place, the syringe containing the dose (and also the air) was injected into the lungs. The needle was removed and the animals were left in  
30 place for several seconds to help prevent them from expectorating the dose. The animal was then removed and allowed to recover before returning to the cage.

Exact dosages were determined by reweighing the dosing needle (on a 4 decimal place balance)  
35 after instillation.

- 31 -

D. Ascertaining Blood Cell Counts / Differentials

The biological activity of pegylated G-CSF was determined by measurement of its effect on both the white blood cell counts and on percentages of different 5 cell types present at defined time points. Total white blood cell count ("WBC"), polymorphonuclear leukocytes ("pmns" i.e., neutrophils), macrophages ("macs"), monocytes ("monos"), lymphocytes ("lymph") and eosinophils ("eos") were variously ascertained and 10 counted. The samples were collected and analyzed by the following methods.

Blood Samples: At a fixed period of time after administration, hamsters were reweighed and then sacrificed by CO<sub>2</sub> asphyxiation. Immediately after 15 death, blood samples were removed via cardiac puncture. Half milliter samples were used for immunoassays, (Example 6, below), to determine relative amounts of pegylated or non-pegylated G-CSF. For blood smears and total white blood cell counts, 0.5 ml samples were 20 placed in tubes containing 0.1 ml of 3% w/v EDTA and mixed.

Lavage: Lavage, the washing and removal of lung fluid, (or bronchoaveolar lavage ("BAL") fluid), was performed in order to ascertain the degree of 25 biological response within the lung. This was performed using 12 x 3 ml washes with phosphate buffered saline (pH 7.2). A small slit was made in the trachea at the level of the fifth tracheal cartilage below the crycoid cartilage such that 3 cm of an 18 G 30 polyethylene tubing ring could be inserted. The leading edge of the tubing was inserted 1.5 cm into the trachea and tied-off with silk.

For washing, a 5 ml glass syringe containing 3 ml of PBS, attached to a 19 G blunt nosed needle was 35 inserted into the cannula. The PBS was injected slowly into the lungs while massaging the throat. The lung

- 32 -

fluid was then withdrawn while continuing the massage. This process was repeated 12 times.

The first 6 ml of lavage fluid was used for immunoassay of protein levels. The fluid was  
5 centrifuged at 300 x g for 10 minutes, and the supernatant was withdrawn. The cells were resuspended in 0.5 ml PBS and added to the remaining 30 ml of lavage fluid. Total cell counts in the lavage fluid were measured using a hemocytometer as well as by Coulter  
10 Counter ("coulter"). To determine the differential counts, a dilute cell suspension was concentrated by centrifugation on a glass slide (Cytospin II™, Shandon Company, Pittsburgh, PA) and the fraction of cell types were measured by using light microscopy to count and  
15 differentiate the observed cells.

E. Procedure for Dose-Ranging Example Involving Sub-Cutaneous Administration

For Example 7 below, involving sub-cutaneous injection, 100 µl of tri-tetra pegylated G-CSF in 1 mM HCl was either instilled or injected sub-cutaneous into the lower backs of male, golden Syrian hamsters. Doses of 0.1 (six animals), 1 (six animals), 10 (nine animals), 50 (six animals), and 100 (nine animals) µg/kg  
20 were administered after anesthetization with Metafane, followed by intra-peritoneal injection of 0.4-0.5 ml of 10mg/ml Brevital®. Animals were found to be awake and mobile 5-10 minutes after anesthetization.  
25

Pulmonary administration via instillation was  
30 performed as described above.

F. Procedure for Intra-Cardiac Comparison Example

For Example 8 below, involving intra-cardiac administration, male golden Syrian hamsters were dosed  
35 via intra-cardiac puncture with 500 µg/kg G-CSF or tri-tetra pegylated G-CSF. In order to find the correct

- 33 -

position of the heart on the hamster, the syringe plunger (27G syringe needle) was withdrawn slightly once the needle was injected. The presence of back-flushed blood indicated that one of the ventricles had been successfully penetrated.

After injection, the animals injected with non-pegylated G-CSF were sacrificed at 0.1, 0.5, 1, 3, 6, 12 and 24 hours (five animals for each time period). Animals injected with pegylated G-CSF were sacrificed at 10 0.1, 1, 6, 12, 24 and 36 hours (five animals at each time period). Animals injected with 100 µl of 1mM HCL were also sacrificed at each time point (three animals for each time period).

Cell counting and differentiation was determined as above, with 0.5 ml samples removed. From these cohorts, further 1 ml samples were taken and the serum was then assayed for the presence of the G-CSF and pegylated G-CSF.

20        G.     Procedure for Immunoassay of Serum Levels of G-CSF or Pegylated G-CSF

As indicated above, serum samples were obtained with the hamsters used in the intra-cardiac study above (injected with either pegylated or 25 non-pegylated G-CSF). To ascertain the length of time pegylated G-CSF vs. non-pegylated G-CSF remained in the blood, the serum samples collected at various time intervals were examined for the presence and amount of G-CSF antigen.

30        The immunoassay was performed using a kit obtained from R & D Systems, (Indianapolis, Indiana) according to the instructions, which are herein incorporated by reference. The results presented herein are shown as relative concentrations at various time 35 intervals, rather than as absolute values, due to

- 34 -

limitations on assay sensitivity when the pegylated material was used.

Pegylated G-CSF Studies

5

EXAMPLE 5

Pulmonary Administration of Pegylated  
G-CSF By Intratracheal Instillation

10

Two studies were done to ascertain the effects of pulmonary administration of pegylated G-CSF, a 6-hour study and a longer, 5-day time course. Controls were also performed using single doses of instilled water,  
15 HCl, and G-CSF (non-pegylated) dissolved in water.

1. 6-Hour Study

The 6 hour study demonstrates that pegylated G-CSF is absorbed from the lung into the bloodstream.

20

Hamsters were instilled according to the above-described protocols with a 50 µg nominal dose of tri-tetra pegylated G-CSF and sacrificed at the time points of 0.1, 0.5, 1, 3, and 6 hours (6 animals for each time point). Blood and BAL samples were removed  
25 for WBC counts, immunoassay and differential determination. (Immunoassay data are presented in Example 6, below).

Results:

WBC: These data are presented in Table 3  
30 (below), and plotted in FIGURE 4. There is an apparent rise in the circulating WBCs between 3 and 6 hours after instillation.

TABLE 3  
WHITE BLOOD CELL COUNT  
AFTER ADMINISTRATION OF PEGYLATED G-CSF

	Time-Hours											
Sample Number	0	0.5	1.0	3.0	6.0	12.0	24.0	36.0	48.0	72.0	96.0	120.0
Average*	5.0	3.7	6.5	7.9	9.3	17.3	28.33	31.2	23.2	12.8	15.8	13.3
Standard Deviation	1.2	1.4	2.8	1.4	1.7	6.3	5.0	10.5	8.7	3.4	3.9	2.3

\*Average of six samples.

- 36 -

Differential cell counts: These data are presented in Table 4, and FIGURE 5. A significant increase in the fraction of neutrophils (as ascertained by polymorphonuclear leukocytes or "pmns") is seen at 5 the 3 and 6 hour time points.

TABLE 4  
DIFFERENTIAL CELL COUNTS

Hrs		PMNS	LYMPHS	MONOS	EOS
0	Avg (6 Samples)	6.0	93.0	0.2	0.2
	Std. Dev.	2.7	3.4	0.4	0.4
0.5	Avg (6 Samples)	3.7	96.0	0.3	0.2
	Std. Dev.	1.6	1.8	0.5	0.4
1.0	Avg (6 Samples)	12.5	87.3	0.2	0
	Std. Dev.	5.4	5.2	0.4	0
3.0	Avg (6 Samples)	40.1	58.5	0.3	0.5
	Std. Dev.	13.9	13.6	0.5	0.8
	Avg (6 Samples)	44.7	54.5	0.2	0.3
6.0	Std. Dev.	12.7	12.2	0.4	0.5

10

Lavage fluid: These data are presented in Table 5 and FIGURE 6. A slight increase in pmns in the lavage fluid is noted about 3 hours after instillation.

- 37 -

TABLE 5

LAVAGE FLUID

Hrs		Coulter	Hemo-	Macs	PMNs
			cytomer	%	%
0	Avg (6 Samples)	5.2	8.6	99.8	0.2
	Std. Dev.	2.6	1.6	0.4	0.4
0.5	Avg (6 Samples)	5.8	9.9	99.8	0.2
	Std. Dev.	3.2	4.1	0.4	0.4
1.0	Avg (6 Samples)	5.6	9.2	99.3	0.5
	Std. Dev.	3.6	1.8	0.8	0.6
3.0	Avg (6 Samples)	5.3	9.0	92.8	7.2
	Std. Dev.	1.9	2.2	9.4	9.4
6.0	Avg (6 Samples)	5.1	10.7	67.7	32.3
	Std. Dev.	3.0	3.1	17.0	17.0

5

2. 5-Day Study

The same materials and methods as used in the 6-hour study were used, and the same parameters were analyzed.

10

Results:

WBC: These data are presented in Table 3 (above), as a continuation of the 6 hour study. The data are plotted in FIGURE 7 which illustrates the overall circulating WBC response to pegylated G-CSF over 15 a 5 day period. There was a rapid rise during the first 24 hours, then a decrease after 36 hours. The values return to base line after 7 days (not shown).

Weight Change: These data are presented in Table 6 and plotted in FIGURE 8. The weight change 20 in the animals over the 5 day period was also recorded. As found for non-pegylated G-CSF previously, some loss in weight is noted after the first day which is then recovered with a steady weight gain over the remaining time of the study.

- 38 -

TABLE 6: ANIMAL WEIGHT AND DIFFERENTIAL CELL TYPES AFTER ADMINISTRATION OF PEGYLATED G-CSF

TIME (h)	0	12	24	36	48	72	96	120	168
Cntrl									
DOSE	105.3	83.2	87.0	84.2	92.3	86.7	87.6	84.2	
WEIGHT	11.3	-1.5	-7.3	2.3	4.0	4.0	10.5	6.1	9.3
DIFF(g)	1.4	1.3	4.0	2.1	2.8	1.6	4.4	10.3	1.3
WBC ( $\times 10^3/\mu\text{l}$ )	9.2	19.3	28.3	31.2	23.2	12.8	15.8	13.3	7.9
RBC ( $\times 10^6/\mu\text{l}$ )	1.6	4.5	5.0	10.5	8.7	3.4	3.9	3.0	2.8
PMN (%)	8.4	9.9	7.9	9.7	8.7	9.6	9.4	9.0	9.2
	1.4	1.7	0.7	0.8	0.8	1.4	1.0	1.3	1.1
6.2	4.4	5.3	5.1	4.1	8.3	3.6	8.0	5.4	
Lymph (%)	80.7	38.5	32.0	38.2	49.5	60.8	52.3	49.2	76.8
	5.7	5.3	6.6	6.0	4.4	8.4	3.8	8.6	5.5
Mono (%)	0.7	0.0	2.5	1.5	0.7	1.7	1.3	0.7	0.7
	0.5	0.0	0.6	1.2	0.5	1.2	1.0	0.8	0.8
EOS (%)	1.2	0.8	1.3	1.7	1.0	1.3	1.5	2.3	1.0
	0.8	1.0	1.2	1.5	0.6	1.0	0.6	1.8	1.1
PMN ( $\times 10^6$ )	1.6	12.6	18.1	18.7	11.4	4.8	7.0	6.4	1.7
	0.7	3.2	3.3	7.5	4.5	2.0	1.8	1.7	0.6
WBC ( $\times 10^6$ )*	8.0	7.8	10.9	9.6	N/A	11.5	8.7	10.7	9.8
	1.4	2.3	1.7	1.8	N/A	2.9	1.4	2.5	3.2
WBC ( $\times 10^6$ )†	9.8	11.9	12.5	11.1	13.5	N/A	12.5	10.9	10.5
	1.7	3.5	3.0	2.1	4.3	N/A	1.0	1.8	1.2
MAC-BAL (%)	99.0	89.2	80.7	84.5	79.7	87.0	88.7	96.2	97.3
	1.1	9.7	18.3	8.6	6.0	5.4	2.7	2.5	1.8
PMN-BAL (%)	0.7	10.6	19.3	14.3	18.5	11.5	8.8	2.3	1.0
	0.5	9.8	18.3	7.7	5.0	4.0	2.3	1.4	1.7
OTHER-BAL (%)	0.3	0.2	0.0	1.2	1.8	1.5	2.5	1.5	1.7
	0.8	0.5	0.0	1.0	1.6	1.6	2.7	1.4	1.6
MAC-BAL ( $\times 10^6$ )	7.9	6.8	8.7	8.1	10.7	10.0	7.8	10.2	9.5
	1.3	1.2	1.7	2.0	3.6	2.5	1.4	2.1	3.1
PMN-BAL ( $\times 10^6$ )	0.1	0.9	2.3	1.4	2.5	1.3	0.8	0.3	0.1
	0.1	0.9	2.5	0.8	1.1	0.6	0.1	0.2	0.1

- 39 -

Six animals were used for each time period. "N/A" indicates data which are not available. For the cell counts and percentages, the top number is the average, the bottom number is the standard deviation.

5    \*\* indicates a Coulter Counter was used. # indicates a hemocytometer was used.

Differential Cell Types: These data are presented in Table 6 (above), and plotted in FIGURE 8. There is a rapid rise in the percentage of circulating 10 neutrophils up to 24 hours, then a steady decline over the remaining period of the study. This correlates with the WBC count, above (Table 3).

Lavage: These data are presented in Table 6 (above), and plotted in FIGURE 10. As can be seen, peak 15 percentage of neutrophils in the lung occurs at 24 hours, and returns to baseline at approximately 120 hours after administration.

3. Controls: Water, 1mM HCl, Anesthetic, and  
20    Non-Pegylated G-CSF in Water

Control experiments were performed according to the materials and methods described above.

Five hamsters were used for each control study for dosing by intratracheal instillation. All hamsters 25 were anesthetized by using inhaled Metafane followed by intraperitoneal injection of Brevital® (except one control group was not given the inhaled anesthetic). All solutions were filtered through a 0.22 $\mu$ m Acrodisk prior to administration. Animals were sacrificed after 24 30 hours. Blood and BAL samples were removed for analysis of cell types and total counts as described above.

For the G-CSF in water control, dried G-CSF was dissolved in water and then instilled at a dose equivalent to 500  $\mu$ g/kg.

35    For the inhaled anesthetic control group, a dosage of 50  $\mu$ g non-pegylated G-CSF was given.

- 40 -

Results

No inhaled anesthetic: These data are shown in Table 7 and the white blood cell counts are graphed in FIGURE 11. As can be seen, a substantial 5 increase in WBC count is found. There is no significant difference in the 24 hour response whether inhaled anesthetic is used or not. This indicates that inhaled anesthetic has no apparent effect on the response to G-CSF after intratracheal administration.

- 41 -

TABLE 7:  
ANESTHETIC CONTROLS

	24 hr. After <u>No Anesthetic</u>		24 hr. After <u>Inhaled Anesthetic</u>	
	Avg 5 Animals	Std. Deviation	Avg 6 Animals	Std. Deviation
Dose ( $\mu$ l)	91.0	8.9	76.7	6.9
Dose ( $\mu$ g)	45.5	4.5	38.4	3.4
Weight diff.	-0.5	1.0	-1.3	1.5
WBC Cnt ( $\times 10^3$ )	21.3	3.6	22.0	5.9
RBC Cnt ( $\times 10^3$ )	7.6	0.2	8.3	1.2
PMN %	60.2	7.3	62.7	6.6
Lymph %	39.2	7.1	36.5	6.4
Mono %	0.4	0.6	0.5	0.6
EOS %	0.2	0.5	0.3	0.5
BAL- Coulter ( $\times 10^6$ )	7.7	2.4	7.6	1.3
BAL-Hemo ( $\times 10^6$ )	9.6	1.7	22.5	0.9
BAL-PMN%	17.6	6.3	25.0	9.4
BAL-MAC%	82.0	6.0	74.8	9.5
BAL-OTHER %	0.0	0.0	0.2	0.4
BAL-MAC ( $\times 10^6$ )	NOT DONE		5.6	1.0
BAL-PMN ( $\times 10^6$ )	NOT DONE		1.9	0.9

5           Effects of HCl or water vehicle: The neutrophil levels in the lung after administration of 50  $\mu$ g G-CSF vs. HCl vehicle vs. water is illustrated in

- 42 -

FIGURE 12. As can be seen, the influx of neutrophils into the lung is by far the greatest in the presence of administered G-CSF. There is no significant difference between the neutrophil levels present in the lung after 5 administration of water or pH 4.0 acid vehicle, indicating that the acid vehicle does not contribute to lung permeability.

#### EXAMPLE 6

10

##### Pharmacokinetics as Ascertained Via Immunoassay

In this study, the pharmacokinetics of pegylated G-CSF were studied in two respects: (1) the 15 transfer of pegylated G-CSF from the lung to the circulation, and (2) the length of time pegylated G-CSF stays in the serum after instillation. Materials and methods are described above.

Transfer of Pegylated G-CSF From the Lung To 20 the Serum: These data are plotted in FIGURE 13 on a relative basis. The data are presented as a comparison of pegylated vs. non-pegylated G-CSF. As can be seen, the pegylated G-CSF transfers to the serum more slowly than non-pegylated G-CSF.

Serum Concentration of Pegylated G-CSF Over 25 Time: The peak serum concentration of the pegylated G-CSF is approximately 4-5 hours after instillation, whereas the peak serum concentration for non-pegylated G-CSF is approximately one hour after instillation. 30 Also, in this assay, the peak concentration for the pegylated material appeared approximately one order of magnitude lower than the peak concentration for the non-pegylated material, but these results may have been influenced by the sensitivity limitations of the 35 immunoassay itself.

- 43 -

Lavage: FIGURE 14 plots data for logarithmic transformation of amounts in the lung of both pegylated G-CSF and non-pegylated G-CSF with absorption rate constants. As can be seen, the pegylated G-CSF is  
5 absorbed with apparent first order kinetics.

#### EXAMPLE 7

10       Dose Ranging Study, Pulmonary Administration of  
Pegylated G-CSF vs SC Injection of Pegylated G-CSF

In this study, routes of administration for pegylated G-CSF were compared over a range of doses. Methods used are described above.

15       Results

Data are presented in Table 9 (instillation data), and Table 9 (sc injection data) and FIGURE 15 (plotting white blood cell count for each). As can be seen, there are similar responses in terms of  
20 total white blood cell count, and various cell differentiation.

- 44 -

TABLE 9:  
DOSE RANGING OF PEGYLATED G-CSF ADMINISTERED  
BY INSTILLATION, ANIMAL WEIGHT, CELL COUNTS  
AND CELL DIFFERENTIALS

5

Treatment (100 $\mu$ l)	0.1 $\mu$ g (6 animals)	1.0 $\mu$ g (6 animals)	10.0 $\mu$ g (9 animals)	50.0 $\mu$ g (6 animals)	100.0 $\mu$ g (9 animals)
Dose (wt/mg)	97.3 4.4 1.8	89.2 7.7 91.6)	(ave.3 animals=	(not avail.)	(ave.3 animals = 93.6)
Weight	-0.3	-5.8	2.2	0.7	1.7
Diff. (24h(g))	3.1 1.3	4.8	3.2	1.2	1.3
Total WBC ( $\times 10^3/\mu$ l)	11.2 2.4 1.0	14.0 4.7 10.8	33.3	42.5 7.4	28.9 9.5
Total RBC ( $\times 10^6/\mu$ l)	8.6 0.6 0.2	9.7 0.8 3.9	12.3	14.7 2.4	9.7 2.1
PMN %	30.3 8.1 3.3	48.2	62.6	60.7	63.6
Lymphocyte %	66.8 10.4 4.2	51.7	36.4	37.3	34.2
Monocyte %	0.2 0.4 0.2	0.2	0.4	1.0	0.8
Eosinophil %	2.7 3.4 1.4	0.0	0.6	1.0	1.4
Counts PMNs	3.3 0.9 9.4	7.3 4.7 5.5	20.4	25.6 4.2	18.6 6.9

- 45 -

The top number in each row is the average, the next number is the standard deviation. For the 0.1  $\mu\text{g}$  treatment, the third number is the standard error of the mean ("SEM").

- 46 -

TABLE 10

DOSE RANGING STUDY OF PEGYLATED G-CSF ADMINISTERED BY SUBCUTANEOUS  
INJECTION: ANIMAL WEIGHT, CELL COUNTS, AND CELL DIFFERENTIALS

Treatment	0.1 µg (100 µl)	1.0 µg (6 animals)	10.0 µg (9 animals)	50.0 µg (6 animals)	100.0 µg (9 animals)
Dose (wt/mg)	93.5 4.2 1.7	91.0 3.2 = 100.0)	(avg. of 3 animals = 100.0)	(not avail.)	(avg. of 3 animals = 94.7)
Weight	3.8	-0.5	2.8	1.0	1.4
Diff. (24h(g))	1.3	7.4	2.8	1.7	0.6
Total WBC (x 10 <sup>3</sup> /µl)	9.7 2.3 0.9	26.4 7.1	41.2 13.3	42.2 6.0	34.6 7.6
Total RBC (x 10 <sup>6</sup> /µl)	8.2 0.7 0.3	9.8 0.7	13.5 4.5	14.0 1.6	10.0 3.5
PMN	26.3	59.0	58.6	59.3	66.3
%	5.1	0.3	4.2	5.6	4.8
	2.1				
Lymphocyte	72.7	39.7	40.3	39.5	31.8
%	4.3	5.5	4.3	6.2	3.7
	1.7				
Monocyte	0.0	0.0	0.6	0.0	0.8
%	0.0	0.0	0.9	0.0	0.4
	0.0				
Eosinophil	1.0	0.7	0.6	0.5	1.1
%	1.6	0.8	0.7	0.8	1.3
	0.6				
Counts PMNs	2.6	15.7	24.3	25.0	22.9
	0.9	5.3	8.5	4.0	5.3
	0.4				

- 47 -

The top number in each row is the average, the next number is the standard deviation. For the 0.1 µg treatment, the third (bottom) number in each row is the SEM.

5           WBC: Particularly, as shown in FIGURE 16, the white blood cell count steadily increased for both forms of administration of pegylated G-CSF. There is a time lag in response at the low dose levels for pegylated G-CSF, because of the time ( $t_{1/2}=6.1$  hours) for  
10 sufficient pegylated G-CSF to penetrate the pulmonary barrier and initiate a response. This lag is not apparent at higher doses, however, and one can see that even the low fractional transfer of pegylated G-CSF to the circulation within approximately one hour at doses  
15 used is sufficient to elicit a maximal response.

#### EXAMPLE 8

20           Elimination Kinetics Of Intra-Cardiac  
Injection of Pegylated vs. Non-Pegylated G-CSF

This study relates to the elimination kinetics and effects of intra-cardiac injection of pegylated G-CSF vs. non-pegylated G-CSF. Comparisons were made of  
25 such intra-cardiac injection to pulmonary administration. For this intra-cardiac administration study, a dose of 500 µg/kg was given to each animal, and 5 animals were sampled for each pegylated G-CSF/non-pegylated G-CSF, at time points of 0.1, 0.5,  
30 1, 3, 6, 12, 24 and 36 hours. For the acid vehicle (pH 4.0) control, 3 animals were used at each time point, except for 0.5 hours, where 2 animals were used. Materials and methods are as described above.

- 48 -

Results

Results are presented in Table 11 and FIGURES 16, 17, and 18. TABLE 11

5

COMPARISON OF PEGYLATED G-CSF  
WITH NON-PEGYLATED G-CSF:  
WHITE BLOOD CELL COUNTS  
AFTER INTRACARDIAC ADMINISTRATION

Table 11: WBC counts and  
PEG G-CSF in The Circulation

Time (hrs)	#	After IC Injection		
		G-CSF	PEG G-CSF	Vehicle
		WBC #s	WBC #s	WBC #s
0.1	avg	5.5	6.1	5.5
	stdv	1.6	1.2	0.3
0.5	avg	5.5	na	5.4
	stdv	1.7	na	1.7
1	avg	7.9	8.2	4.4
	stdv	3.6	1.5	3.7
3	avg	11.8	na	7.2
	stdv	1.5	na	4.3
6	avg	11.6	11.2	8.1
	stdv	4.0	4.9	2.6
12	avg	25.0	22.0	6.1
	stdv	5.9	6.2	3.8
24	avg	27.1	27.2	8.1
	stdv	12.1	6.7	4.6
36	avg	na	37.4	11.6
	stdv	na	14.9	0.2

10

WBC count: Table 11 shows data for white blood cell counts for (i) non-pegylated G-CSF, (ii) pegylated G-CSF, and (iii) acid vehicle alone (HCl, pH 4.0). These data are plotted in FIGURE 16. As can be seen,

- 49 -

there is an increase in white blood cell count after a single intra-cardiac injection of 500 µg/kg G-CSF, whether pegylated or non-pegylated, and this increase is not seen with the control.

5           Pulmonary administration vs. Intra-Cardiac Administration: A comparison was made between previous data obtained for the WBC response after intra-tracheal instillation and the intra-cardiac injection of pegylated G-CSF. These data are plotted in FIGURE 17.

10           As can be seen, surprisingly, the white blood cell profiles appear to be similar for both routes of administration, whether through the lung or directly to the blood via the heart. This is surprising because a time lag would have been expected. As demonstrated by  
15           immunoassay data above, roughly half of the instilled dose is available for absorption from the lung to the blood stream. The present study indicates that even a small fraction of the pegylated G-CSF presented to the circulation within 1 to 2 hours post-dosing would be  
20           sufficient to exert a profound effect on WBC numbers.

When non-pegylated G-CSF is compared (pulmonary administration vs. intra-cardiac injection), there are apparent differences in response time.

FIGURE 18.

25           While the present invention has been described in terms of preferred embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations which come  
30           within the scope of the invention as claimed.

- 50 -

WHAT IS CLAIMED IS:

1. A dispersion of particles consisting essentially of a pegylated protein, optionally in a pharmaceutically acceptable carrier.
2. A dispersion according to claim 1 wherein the mass median diameter of said particles is less than 10 $\mu\text{m}$ .
- 10 3. A dispersion according to claim 2 wherein the mass median diameter of said particles is between 0.5 and 5  $\mu\text{m}$ .
- 15 4. A dispersion according to claim 1 wherein said protein which is pegylated is selected from the group consisting of a cytokine, a growth factor, plasminogen activator and a proteinase inhibitor.
- 20 5. A dispersion according to claim 4 wherein said protein which is pegylated is a cytokine.
6. A dispersion according to claim 5 wherein said cytokine is a hematopoietic factor.
- 25 7. A dispersion according to claim 6 wherein said hematopoietic factor is selected from the group consisting of G-CSF, SCF, EPO, GM-CSF, CSF-1, IL-1, IL-2, and IL-6.
- 30 8. A dispersion according to claim 4 wherein said protein which is pegylated is a growth factor.
- 35 9. A dispersion according to claim 8 wherein said growth factor is selected from the group consisting of human and animal growth hormone.

- 51 -

10. A dispersion according to claim 4 wherein said protein which is pegylated is a plasminogen activator.

5

11. A dispersion according to claim 10 wherein said plasminogen activator is selected from the group consisting of tPA, urokinase and streptokinase.

10

12. A dispersion according to claim 1 wherein said polyethylene glycol has a molecular weight of between about 500 and 20,000.

15

13. A dispersion according to claim 12 wherein said molecular weight is at least about 600.

14. A dispersion according to claim 13 wherein said molecular weight is about 6000.

20

15. A dispersion according to claim 1 wherein said polyethylene glycol is capable of being in solid form.

25

16. A dispersion according to claim 1 wherein said pegylated protein contains more than one molecule of polyethylene glycol.

30

17. A dispersion according to claim 1 wherein said pegylated protein contains 2 to 5 polyethylene glycol molecules.

35

18. A dispersion according to claim 1 wherein said particles are in aqueous form.

19. A dispersion according to claim 1 wherein said particles are in non-aqueous form.

- 52 -

20. A dispersion according to claim 19  
comprised of powder particles.

5 21. A dispersion according to claim 20  
wherein the mass median diameter of said particles is  
less than 10  $\mu\text{m}$ .

10 22. A dispersion according to claim 20  
wherein said mass median diameter of said particles is  
between 0.5 and 5  $\mu\text{m}$ .

15 23. A dispersion of particles wherein said  
particles consist essentially of pegylated G-CSF.

24. A dispersion of pegylated G-CSF  
particles, each of said particles containing a  
pharmaceutically acceptable carrier.

20 25. A method for the pulmonary administration  
of a pegylated protein, comprising depositing an  
effective amount of said pegylated protein optionally in  
a pharmaceutically acceptable carrier in the lungs of a  
mammal in need thereof while the mammal is inhaling.

25 26. A method according to claim 25 wherein  
said pegylated protein is in the form of a solution in  
an aqueous medium or a suspension in a non-aqueous  
medium.

30 27. A method according to claim 26 wherein  
said pegylated protein optionally in a pharmaceutically  
acceptable carrier is in the form of a dry powder.

- 53 -

28. A method according to claim 27 wherein said dry powder has a mass median diameter of said particles of less than 10  $\mu\text{m}$ .

5 29. A method according to claim 28 wherein said mass median diameter of said particles is between 0.5 and 5  $\mu\text{m}$ .

10 30. A method according to claim 26 wherein said mass median diameter of said protein which is pegylated is selected from the group consisting of a cytokine, a growth factor, plasminogen activator, and proteinase inhibitor.

15 31. A method according to claim 30 wherein said protein which is pegylated is a cytokine.

32. A method according to claim 31 wherein said cytokine is a hematopoietic factor.

20 33. A method according to claim 32 wherein said hematopoietic factor is selected from the group consisting of G-CSF, SCF, EPO, GM-CSF, CSF-1, IL-2, and IL-6.

25 34. A method according to claim 30 wherein said protein which is pegylated is a growth factor.

30 35. A method according to claim 34 wherein said growth factor is selected from the group consisting of human and animal growth hormone.

35 36. A method according to claim 30 wherein said protein which is pegylated is a plasminogen activator.

- 54 -

37. A method according to claim 36 wherein said plasminogen activator is selected from the group consisting of tPA, urokinase and streptokinase.

5 38. A method according to claim 25 wherein said protein is pegylated with at least one polyethylene glycol molecule having a molecular weight of between about 500 and 20,000.

10 39. A method according to claim 38 wherein said molecular weight is at least about 600.

40. A method according to claim 39 wherein said molecular weight is about 6000.

15 41. A method according to claim 25 wherein said protein is pegylated with at least one polyethylene glycol molecule, said polyethylene glycol molecule being capable of being in solid form.

20 42. A method according to claim 25 wherein said protein is pegylated with more than one molecule of polyethylene glycol.

25 43. A method according to claim 42 wherein said protein is pegylated with 2 to 5 polyethylene glycol molecules.

30 44. A method according to claim 25 wherein said pegylated protein is delivered to the lungs of said mammal from a mechanical device.

35 45. A method according to claim 44 wherein said mechanical device is a nebulizer, metered dose inhaler or powder inhaler.

- 55 -

46. A method according to claim 45 wherein said mechanical device is a nebulizer.

47. A method according to claim 46 wherein  
5 said nebulizer is ultrasonic.

48. A method for the pulmonary administration  
of pegylated G-CSF, comprising depositing an effective  
amount of said pegylated G-CSF optionally in a  
10 pharmaceutically acceptable carrier in the lungs of a  
mammal in need thereof while the mammal is inhaling.

49. A method according to claim 48 wherein  
said pegylated G-CSF optionally in a pharmaceutically  
15 acceptable carrier is tri-tetra pegylated G-CSF.

50. A method according to claim 49 wherein  
said tri-tetra pegylated G-CSF optionally in a  
pharmaceutically acceptable carrier contains at least  
20 one polyethylene glycol molecule having a molecular  
weight of at least about 600.

51. A method of claim 50 wherein said  
molecular weight is about 6000.

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9





FIG. 10



SUBSTITUTE SHEET (RULE 26)

FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15






FIG. 16




9 / 10

FIG. 17



10 / 10

FIGURE 18  
Comparison of the response to 500 $\mu$ g/kg  
G-CSF after intratracheal instillation and  
after intra cardiac injection



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/01875

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 A61K9/00 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 473 268 (IMPERIAL CHEMICAL INDUSTRIES PLC) 4 March 1992 see claims see page 4, line 17 - line 24 see page 10, line 49 - line 56 ---	1-51
Y	EP,A,0 505 123 (AMGEN INC.) 23 September 1992 see the whole document ---	1-51
Y	WO,A,90 05534 (GENENTECH INC.) 31 May 1990 see claims see page 7, line 38 - line 39 see page 9, line 4 ---	1-51
		-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

1

Date of the actual completion of the international search

19 May 1994

Date of mailing of the international search report

30.05.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Scarpioni, U

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 94/01875

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,93 00109 (GENENTECH INC.) 7 January 1993 see claims 1,6,8,29-32 see page 22, line 1 - line 3 see page 22, line 16 - line 28 ---	1-51
Y	EP,A,0 400 762 (CETUS CORPORATION) 5 December 1990 see claims 1,4,6,9 see page 3, line 51 - line 52 see page 3, line 56 - line 57 see page 4, line 7 - line 15 ----	1-51
Y	WO,A,90 07938 (CETUS CORPORATION) 26 July 1990 see claims see example V -----	1-51

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US 94/01875

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark:** Although claims 25-51 are directed to a method of treatment of the human/animal body by therapy (rule 39.1(iv)PCT), the search has been carried out and based upon the alleged effects of the composition.
2.  Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No

PCT/US 94/01875

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0473268	04-03-92	AU-A-	8123891	30-01-92
		GB-A, B	2246295	29-01-92
		JP-A-	5032559	09-02-93
EP-A-0505123	23-09-92	AU-B-	643141	04-11-93
		AU-A-	1747692	21-10-92
		CN-A-	1066192	18-11-92
		NZ-A-	241954	26-01-94
		WO-A-	9216192	01-10-92
		US-A-	5284656	08-02-94
WO-A-9005534	31-05-90	AU-A-	4660789	12-06-90
		CA-A-	2003743	23-05-90
		DE-T-	68906366	02-12-93
		EP-A, B	0372752	13-06-90
		JP-T-	4502011	09-04-92
WO-A-9300109	07-01-93	AU-A-	2147192	25-01-93
EP-A-0400762	05-12-90	US-A-	4818769	04-04-89
		AU-B-	587065	03-08-89
		AU-A-	6294386	26-03-87
		CA-A-	1297003	10-03-92
		DE-A-	3684755	14-05-92
		EP-A, B	0219979	29-04-87
		JP-A-	62123129	04-06-87
		US-A-	5102872	07-04-92
		US-A-	5100664	31-03-92
WO-A-9007938	26-07-90	US-A-	4902502	20-02-90
		AU-A-	4958390	13-08-90
		CA-A-	2008142	23-07-90
		US-A-	5089261	18-02-92